Publications and Presentations

Filter By:

ARRY-380

06/01/2015

American Society of Clinical Oncology Meeting

ONT-380 in the Treatment of HER2+ Breast Cancer Central Nervous System (CNS) Metastases (Mets)

C. Ferrario, et al.

Binimetinib

05/31/2015

American Society of Clinical Oncology Meeting

SUCCESSFUL IMPLEMENTATION OF A NOVEL TRIAL MODEL – THE SIGNATURE PROGRAM

J. Peguero, et al.

Filanesib

05/31/2015

American Society of Clinical Oncology Meeting

The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma

S. Lonial, MD, et al.

Filanesib

05/31/2015

American Society of Clinical Oncology Meeting

A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma

J. A. Zonder, MD, et al.

Encorafenib

05/30/2015

American Society of Clinical Oncology Meeting

A Phase 1/b2 Study of BRAF Inhibitor (BRAFi) Encorafenib (ENCO) Plus MEK Inhibitor (MEKi) Binimetinib (BINI) in Cutaneous Melanoma Patients Naive to BRAFI Treatment

R. Sullivan, et al.

Binimetinib

05/30/2015

American Society of Clinical Oncology Meeting

A phase Ib/II study of MEK162 (binimetinib) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST)

P.Chi, et al.

Binimetinib

05/30/2015

American Society of Clinical Oncology Meeting

A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum

B. J. Monk, MD, et al.

Binimetinib

05/30/2015

American Society of Clinical Oncology Meeting

A Phase 1b dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer

R. N. Grisham, MD, et al.

Encorafenib

04/20/2015

American Association for Cancer Research Annual Meeting

Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target

C. Krepler, et al.

Binimetinib

04/19/2015

American Association for Cancer Research Annual Meeting

Evaluation of the nonclinical activity of the MEK inhibitor binimetinib (MEK162) in combination with paclitaxel in PDX models of HGSOC

S. Winski, et al.